Ocrelizumab's brain impact in progressive MS examined
NCT ID NCT05974852
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study analyzed MRI scans from 732 people with primary-progressive multiple sclerosis who took part in the ORATORIO trial. Researchers wanted to see if ocrelizumab changes a part of the brain called the choroid plexus, which may be involved in inflammation. The study was observational, meaning it looked back at existing data rather than testing a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Buffalo Neuroimaging Analysis Center
Buffalo, New York, 14203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a blood pressure pill slow MS disability?
- Could a simple injection replace an IV for MS treatment?
- Could a common supplement fight fatigue in progressive MS?
- Tears may replace spinal taps for MS diagnosis
- Nurse-Led video calls aim to empower MS patients
- Cheaper MS drug could match pricey standard in major trial